PHD2/3 deletion significantly enhances T-cell activation and effector functions, improving the therapeutic responses to adoptive T-cell transfer in tumor-bearing mice, in various models, including the challenging autochthonous TiRP melanoma model. Here, EGLN1 is linked to neoplasm.